Literature DB >> 19827989

Therapy of community-acquired acute bacterial meningitis: the clock is running.

M Klein1, H W Pfister, S L Leib, U Koedel.   

Abstract

Despite antibiotic therapy and supportive intensive medical care, bacterial meningitis remains a disease with high mortality and morbidity. Rapid recognition of symptoms is crucial to direct physicians quickly towards appropriate diagnostic measures and, initially, empiric antibiotic therapy. It has become evident that time from arrival at the hospital to application of the first dose of antibiotics is a crucial independent factor that influences outcome. Here, we review the clinical and laboratory presentation of community-acquired bacterial meningitis and the antibiotic regiments that are currently recommended for its treatment; future therapeutic options are also discussed. Finally, suggestions for the approach to a patient with suspected bacterial meningitis are presented.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19827989     DOI: 10.1517/14656560903277210

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  11 in total

Review 1.  [Bacterial infections of the central nervous system].

Authors:  M Klein; H-W Pfister
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

2.  β-Lactam resistance, serotype distribution, and genotypes of meningitis-causing Streptococcus pneumoniae, Rio de Janeiro, Brazil.

Authors:  David E Barroso; Daniel Godoy; Terezinha M P P Castiñeiras; Mary M Tulenko; Maria C Rebelo; Lee H Harrison
Journal:  Pediatr Infect Dis J       Date:  2012-01       Impact factor: 2.129

3.  Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection.

Authors:  Thomas J Hannan; Indira U Mysorekar; Chia S Hung; Megan L Isaacson-Schmid; Scott J Hultgren
Journal:  PLoS Pathog       Date:  2010-08-12       Impact factor: 6.823

4.  Arterial cerebrovascular complications in 94 adults with acute bacterial meningitis.

Authors:  Matthias Klein; Uwe Koedel; Thomas Pfefferkorn; Grete Zeller; Bianca Woehrl; Hans-Walter Pfister
Journal:  Crit Care       Date:  2011-11-23       Impact factor: 9.097

Review 5.  Headaches attributable to infectious diseases.

Authors:  Jonathan Gladstone; Marcelo E Bigal
Journal:  Curr Pain Headache Rep       Date:  2010-08

6.  Evolution of antimicrobial resistance and serotype distribution of Streptococcus pneumoniae isolated from children with invasive and noninvasive pneumococcal diseases in Algeria from 2005 to 2012.

Authors:  N Ramdani-Bouguessa; H Ziane; S Bekhoucha; Z Guechi; A Azzam; D Touati; M Naim; S Azrou; M Hamidi; A Mertani; A Laraba; T Annane; S Kermani; M Tazir
Journal:  New Microbes New Infect       Date:  2015-03-26

7.  Outcome of patients with acute bacterial meningitis in a teaching hospital in Ethiopia: A prospective study.

Authors:  Esayas Kebede Gudina; Markos Tesfaye; Andreas Wieser; Hans-Walter Pfister; Matthias Klein
Journal:  PLoS One       Date:  2018-07-18       Impact factor: 3.240

8.  Antimicrobial sensitivity profile and bacterial isolates among suspected pyogenic meningitis patients attending at Hawassa University Hospital: Cross-sectional study.

Authors:  Demissie Assegu Fenta; Kinfe Lemma; Henok Tadele; Birkneh Tilahun Tadesse; Birrie Derese
Journal:  BMC Microbiol       Date:  2020-05-19       Impact factor: 3.605

9.  Leukocyte attraction by CCL20 and its receptor CCR6 in humans and mice with pneumococcal meningitis.

Authors:  Matthias Klein; Matthijs C Brouwer; Barbara Angele; Madelijn Geldhoff; Gabriel Marquez; Rosa Varona; Georg Häcker; Helga Schmetzer; Hans Häcker; Sven Hammerschmidt; Arie van der Ende; Hans-Walter Pfister; Diederik van de Beek; Uwe Koedel
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

10.  Adjunctive dexamethasone therapy in unconfirmed bacterial meningitis in resource limited settings: is it a risk worth taking?

Authors:  Esayas Kebede Gudina; Markos Tesfaye; Aynishet Adane; Kinfe Lemma; Tamiru Shibiru; Andreas Wieser; Hans-Walter Pfister; Matthias Klein
Journal:  BMC Neurol       Date:  2016-08-26       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.